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Abstract
Radiotherapy alone or in combination with chemotherapy/surgery is widely used for treatment of cancers. It
reduces tumor growth and prevents metastasis. While ionizing radiation activates caspase cascade resulted in
apoptosis in cancer cells, it also stimulates tumor cell re-population that leads to reduce the effectiveness of the
radiation therapy. This review describes the mechanisms for paradox role of caspase cascade in cancer therapy
and discusses the logical and practical strategies for improvement the therapeutic index of radiotherapy through
enhancement of radiosensitivity and decreasing the rate of tumor recurrence.
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Background
Radiotherapy is one of the helpful clinical procedure for
treatment of different types of human malignancies espe-
cially lung, thyroid, breast, colon, prostate and brain
cancers. Nearly 50% of all cancerous patients are receiving
ionizing radiation (IR) at some stages of their treatments
[1, 2]. Following irradiation, cancer cell death may occur
mainly through necrosis, autophagy and apoptosis of
which autophagy has more complex role and might pro-
mote cell survival [3–5]. IR prolongs patient’s survival
through decreasing proliferative capacity and killing
tumor cells [6–8]. However, re-population of tumor cells
during or after radiotherapy is an important obstacle to
achieve the desired response [9, 10]. Since death of high
percent of tumor cell is a desirable response in radiother-
apy regimen, identification of the limiting factors such as
cellular proliferation and intrinsic radioresistance are very
important in cancer treatment [6, 9, 11, 12]. Escaping
from programmed cell death or apoptosis is one of the
popular theories that explain cancer cell radioresistance
[1, 13]. Caspase cascade as an apoptosis mediator in radi-
ation therapy has been described to activate signal trans-
duction pathways and expression of survival proteins [14].
In this review, the paradox role of caspase cascade in adju-
vant therapy of the cancer by IR is discussed.
Caspase cascade functions
Caspases (cysteine-aspartic proteases, cysteine aspartases or
cysteine-dependent aspartate-directed proteases) are a fam-
ily of protease enzymes that have critical roles in control-
ling homeostasis in apoptosis and inflammation processes
[6]. On the basis of the mechanisms of actions, caspases
have been categorized into initiators (apical: CASP2,
CASP8, CASP9 and CASP10) and effectors (executioner:
CASP3, CASP6, and CASP7). It is believed that caspases
are present as inactive monomeric precursor enzymes that
must be dimerized for full activation [11, 13, 15–17].
Apoptosis
Apoptosis is a programmed cell death that is involving
degradation of the cellular component such as nuclear
DNA, the Golgi, endoplasmic reticulum (ER) and hydroly-
sis of mitochondrial networks by a group of cysteine
proteases called caspase. A variety of stimuli including IR,
chemotherapeutic drugs, death receptors-mediated pro-
cesses like tumor necrosis factor α [TNFα], growth factor
withdrawal, loss of cell adhesion (anoikis) and cytoskeletal
damage might promote apoptosis pathway through activa-
tion of the caspase cascade [18].
Apoptosis inhibition
Caspase family have important roles in various diseases and
it has been shown that caspase deficiency results in tumor
development [19–21]. Suppression of caspase activation
can be promoted by several proteins including: Bcl-2,
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Inhibitors of Apoptosis Proteins family (IAPs) and Cytokine
Response Modifier A (CrmA) [22, 23]. Bcl-2 is an anti-
apoptotic effector protein which prevents the distribution
of pro-apoptotic proteins such as Bax in the mitocondria
[24]. Human IAPs namely XIAP, c-IAPl, C-IAP2, NAIP,
Livin and Survivin have been described [25]. CrmA pre-
vents caspase dimerization for full activation. Generally,
these groups of proteins inhibit cell death through the
inhibition of caspase and suppression the activity of pro-
apoptotic proteins like as Bax, Bad, Bim and Noxa and also
by augmentation of the activity or expression of anti-
apoptotic proteins like as Bcl-2, IAPs and CrmA [26].
Radiation-induced apoptosis
Following exposure to IR, reactive oxygen species (ROS)
and free radicals are generated which induce DNA
damages. Double-Strand Breaks (DSBs), is the most abun-
dant and toxic DNA damage which results from the ex-
posure to one Gy of IR [27]. Following of DNA damage,
cell cycle arrest and DNA repair are activated. Also two
important pathways namely ATM-CHK2 (Ataxia Telangi-
ectasia Mutated-Checkpoint Kinase 2) and ATR-CHK1
axis (Ataxia Telangiectasia and Rad3-related Checkpoint
Kinase 1) are activated and induced by DSBs and DNA
single-strand breaks (SSBs), respectively [12]. These
pathways have overlapping functions and act in parallel
with each other [12, 28]. CHK2 and CHK1 phosphorylate
different positions of the p53 which results in its dissoci-
ation from mdm2 (mouse double minute 2 homolog). P53
as a tumor suppressor has important role in initiation and
prevention of the cancer. P53 has been named “guardian
of the genome” because of its essential role in the
selection of cell death or cell survival [29]. P53 activation
regulates DNA repair processes and cell-cycle arrest that
occurs at G1-S and G2-M transitions [3, 27]. Actually, the
degree of DNA damage-repair is very prominent to deter-
mine whether cell survival or cell death [30]. Briefly, the
p53 transcription factor responds to numerous cellular
stresses and eliminates cells containing oncogenic lesions
or damaged DNA, thus preventing tumor development
[12]. Defective DNA repair results in promotion of aneu-
ploidy and progression of cancer. The importance of p53
in sensitivity to radiation was discussed by several studies.
For instance, resistance to radiation have been found in
thymocytes lacking functional p53, whereas wild type p53
are extremely sensitive to radiation [31]. Moreover, radio-
sensitive apoptotic pathway is induced in colonic and
leukemia malignant cells with overexpression of wild type
p53 [32, 33]. In Summary, p53 expression has pivotal role
in induction of p53-dependent apoptosis and cells with
high p53 mRNA expression are more susceptible to
radiation-induced apoptosis [34].
IR frequently induces intrinsic (mitochondrial mediated),
extrinsic (death receptor mediated) and membrane (ceramide
production) apoptotic pathways. Intrinsic and extrinsic
apoptotic pathways are activated by p53 and membrane
stress pathway is promoted by contribution of ceramide as a
second messenger (Fig. 1) [35].
Extrinsic apoptotic pathway
In the extrinsic apoptotic pathway, a complex is formed
between the death receptors such as CD95 (APO-1/Fas),
TNF receptor 1 (TNFRI), TNF-related apoptosis-inducing
ligand-receptor 1 (TRAIL-R1) and extracellular ligands
including CD95 ligand (CD95L), lymphotoxin-α and TNF-
related apoptosis-inducing ligand (TRAIL-1). It should be
noted that activation of p53 by radiation causes downstream
transactivation of both death receptors and ligands [35, 36].
Complex formation between the death receptors and their
cognate death ligands results in receptor trimerization and
clustering of the death domain receptors. Also, recruitment
of an adaptor protein like as fas-associated death domain
(FADD) mediated by Death Domain (DD) lead to the
formation of the death inducing signaling complex (DISC)
by interaction between pro-caspase 8 and FADD. The
resulting complex activates caspase-8 as a caspase initiator
which in turn triggers executioner caspases 3 and 7 and as a
consequence results in the cell death [17, 35].
Intrinsic apoptotic pathway
Apoptotic mitochondria pathway is regulated by Bcl-2
family. Following p53 activation in response to a stress such
as IR, PUMA (p53 Upregulated Modulator of Apoptosis)
expression is results in the release of BAX a member of the
Bcl-2 family. The Bcl-2 family may act either as anti-
apoptotic (e.g. Bcl-2, Bcl-xl) or pro-apoptotic (e.g. Bax,
BAD). Bax expression leads to Mitochondrial Outer Mem-
brane Permeabilization (MOMP) that results in release of
the cytochrom C from mitochondria intermembrane space
to cytoplasm [35]. Moreover, IR may increases the forma-
tion of O2
• in mitochondria directly which in turn triggers
the release of cytochrome C [37]. Results of the recent
studies suggest that cytochrom C, dATP and an adapter
protein namely apoptotic protease-activating factor-1
(APAF-1) are involving in the formation of a large multi-
meric complex called apoptosome. Activation of the pro-
caspase 9 through with apoptosome leads to the cell death.
Membrane stress pathway
In contrast to intrinsic and extrinsic pathways, membrane
stress pathway is independent of p53 [38]. Release of
Ceramid as a second messenger is necessary to initiate
this pathway. Ceramid can be formed through two
different ways. Oxidative damages of ROS on lipid mem-
brane results in activation of sphingomyelinase which in
turn hydrolyze sphingomyelin of the membrane to cer-
amide [35, 39]. Also the high dose of IR induces DSBs
which activates the synthesis of ceramide [40]. Ceramide
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promotes MAP/ERK (Mitogen Activated Protein/Extra-
cellular Signal-Regulated Kinase) (MEKK) pathway which
in turn activates Mitogen-Activated Protein Kinase 8
(MAPK8) and of the effector caspases-1, -3 and -6 that
promote the cell death pathway [35].
Suppression of radiation-induced apoptosis
IR induces multiple pro-survival signaling pathways
through activation of ERK, c-Jun N-terminal Kinase (JNK),
p38 MAPK and overexpression of COX-2 that can suppress
apoptosis and reduce the cytocoxicity of radiation in radio-
resistance cancer cells. The mechanisms of these survival
signaling pathways induce cell viability and inflammation
are as follows:
Radiation- induced ERK1/2 pathway
IR activates human epidermal growth factor receptor
(HER) signaling pathway which consists from four plasma–
membrane bound receptor tyrosine kinase HER1, HER2,
HER3 and HER4 [41]. IR mimics the behavior of EGF and
induces HER dimerization which is followed by autophos-
phorylation of several tyrosine residues in the c-terminal of
the regulatory tail of the receptor. HER activation
stimulates Ras/Raf/MEK/ERK pathways through the ex-
change of GDP bound to Ras for GTP [35]. MEK activates
ERK1/2 through phosphorylation of threonine and tyrosine
which in turn inactivate apoptosis through inhibition of
some pro-apoptotic proteins such as Bim, Bad, caspase 9. It
also enhances expression of anti-apoptotic proteins such as
Mcl-1, Bcl-xl. In summary radiation-induced activation of
ERK1/2 signaling results in apoptosis suppression in
irradiated cell by enhancing the activity/expression of anti-
apoptotic proteins such as Bcl-xl and prevention of the
activity of pro-apoptotic proteins [42–45].
Radiation-induced Akt signaling pathway
Upon HER hetrodimerization and autophosphorylation,
PI3K/AKT1 and Ras/Raf/MAPK pathways are activated.
AKT is a vital pro-survival factor that suppresses the
apoptotic signaling pathway and leads to activation of
pro-survival pathways and cell development [46]. Follow-
ing HER dimerization and autophosphorylation of tyro-
sines in the regulatory intracellular domains of the
receptor, six docking sites are formed [47]. Binding of the
p85 regulatory subunit of the class 1 phosphatidylinositol
3-kinases (PI3K) to docking sites recruits the p10 subunit
Fig. 1 A summary of extrinsic, intrinsic and membrane stress apoptotic pathways. a DNA damages lead to activation of p53 that promotes the expression
of pro-apoptotic proteins such as BAX and consequently permeabilization of the outer membrane of mitochondria and release of cytochrome C followed
by formation of a large multieric complex namely Apoptosom through participation of cytochrome C, dATP and apoptotic protease-activating factor-1
(APAF-1). b Activation of p53 by ionizing radiation leads to downstream transactivation of death receptor and death ligand that trigger extrinsic apoptotic
pathway followed by complex formation between death receptor and its cognate ligand. Complex formation results in receptor trimerization and
consequently formation of death inducing signal complex (DISC) by participation of FADD (Fas-associated death domain) mediated by DD (death domain).
c Apoptosis might be prompted by production of ceramide as a second messanger which is activated by double strand breaks (DSBs) and reactive oxygen
species (ROS) and as a result activation of sphingomyelinase followed by hydrolysis of sphyngomyelin and release of ceramide. The outcome of apoptosis
is caspase activation which results in cell death due to production of apoptosome, death inducing signaling complex (DISC) and ceramide in intrinsic,
extrinsic and memberane stress apoptotic pathways, respectively
Rahmanian et al. Journal of Biomedical Science  (2016) 23:88 Page 3 of 13
of PI3K as a catalytic subunit to form fully activated phos-
phatidylinositol 3-kinase (PI3K) enzyme. PI3K converts
phosphatidylinositol-4,5-biphosphate (PIP2) to phos-
phatidylinositol (3,4,5)-triphosphate (PIP3) which activates
phosphoinositide-dependent kinase (PDK) [48]. AKT is
activated at first through phosphorylation of Thr 308
present in its kinase domain by activated PDK1 and then
by phosporylation of Ser 473 present in its C-
terminal domain by PDK2 [42, 48]. Activated AKT
negatively regulates apoptotic pathways at least
through seven mechanisms. I) phosphorylation and
inhibition of the pro-apoptotic proteins of Bcl-2 family
(e.g. Bad, Bax, Bim) [46] and inhibition of the expression of
the pro-apoptotic proteins (Bim, Noxa) [49], II) phosphor-
ylation of NF-КB as a pro-survival transcription factor that
leads to expression of the anti-apoptotic proteins including
Bcl-2 and Bcl-xl. [50], III) activation of XIAP (X-linked
inhibitor of apoptosis protein) as a pro-survival protein
that inhibits caspase 3, 7, 9 and results in suppress apop-
tosis [51], IV) activation of m-TOR kinase signaling path-
way and other pro-survival signaling pathway that results
in activation of mcl-1 as an anti-apoptotic protein [52], V)
direct inhibition of the pro-apoptotic transcription factor
Foxo3a as a positive regulator which induces expression of
pro-apoptotic proteins [53], VI) phosphorylation of glyco-
gen synthase kinase which results in inhibition of apoptotic
induction by this enzyme under hypoxia during radiation
therapy [54], VII) direct activation of non-homologous end
joining (NHEJ) as a pathway which repairs DSBs damages
and results in enhanced cell survival [55]. In summary, all
the above mentioned mechanisms can be activated by
AKT signaling pathway, which results in cancer cell devel-
opment in response to radiation [42].
Radiation-induced JAK-STAT signaling pathway
IR activates JAK-STAT signaling pathway by increasing in
the phosphorylation of Janus-Associated kinase 2 (JAK-2)
and consequently Signal Transducer and Activator of
Transcription (STAT). Translocation of STAT to the cell
nucleus increases the levels of Bcl2/Bcl-xl proteins that
are leading to decrease caspase-3 activity, tumor survival
and radioresistant lung cancer cells. Niclosamide as an
effective STAT3 inhibitor has shown to block effectively
STAT3/Bcl2/Bcl-xl and to reduce the radioresistance in
animal lung cancer xenografts [56, 57].
Radiation-induced Cox-2 overexprresion
Cyclooxigenases or prostaglandin synthases (COXs or
PGH synthase) also known as COX-1, COX-2 and COX-3
are required enzymes for the formation of prostanoids
including prostaglandins and thromboxane. Of three
isozymes, COX-2 has aggressive behaviors in tumors and
is overexpressed in a variety of malignant tumors such as
melanoma and breast cancer [58, 59]. Moreover, IR
increases the production of COX-2 proteins. Several pro-
survival pathways are mediated by COX-2 and result in
tumor progression. Prostaglandin E2 (PGE2) is one of the
main products of these pathways that has important role
in cell proliferation, cell migration, tumor invasion and
cell death [56]. PGE2 increases intracellular cAMP levels
which activates protein kinase A (PKA) and phos-
phatidylinositol 3-kinase (PI3K) enzymes. PGE2 increases
the level of Bcl-2 in adenocarcinoma and activates MAPK
pathway through transactivates EGFR by increase in
amphiregulin levels as a well-known EGFR ligand [56, 60,
61]. Yamakie et al. reported that PGE2 activated sarcoma
kinase in non-small cell lung cancer through phosphoryl-
ation and activation of STAT3 [62]. Briefly overexpression
of COX-2 in cancer cells mediates several pro-survival
pathways including; MAPK/ERK, JAK/STAT, PI3K/AKT
that enhance expression of pro-survival proteins such as
NF-КB, Bcl-2 and Bcl-xl, IAP. It inhibits expression of
pro-apoptotic proteins including Bad, Bax, and Bim that
lead to inactivate caspase cascades and subsequently
suppress apoptotic pathway. Therefore it seems that
COX-2 inhibitors such as celecoxib might be useful to en-
hance the therapeutic index of chemoradiation through
sensitization of tumor cells and as well as protection of
normal cells to IR [56, 60, 61]. Radiosensitivity effect of
COX-2 inhibitors will discuss in next section.
Activation of radiation–induced apoptosis: caspase inducers
It is well known that the defects in caspase cascade activa-
tion lead to tumor progression and metastasis while its acti-
vation by compounds sensitizing tumor cells to IR result in
induction of apoptosis, reduction in tumor size and control
of cancer development. The amplification in expression of
CASP3 protein after exposure to radiation induces the cell
death through apoptotic pathway [63, 64]. It has been
demonstrated that apoptotic receptor agonists such as
monoclonal antibody ligands that bind specifically to
TRAIL receptors (TNF-related apoptosis-inducing ligand)
in combination with IR cause a synergistic apoptotic effect
through the activation of caspase cascade pathway [65–68].
Radiosensitizers
Compounds known as radiosensitizers enhance therapeutic
index of radiotherapy through inducing apoptosis. One of
the most important reasons for the resistance to chemo-
therapy and /or radiotherapy is the presence of hypoxic
cells in solid tumors because of insufficient blood supply to
these tumors. Oxygen by formation of free-radical DNA
damage increases the effectiveness of radiation and it is
known as a potential radiosensitizer. Nitoaromatic and
nitroheterocyclic compounds act as radiosensitizers by for-
mation of nitro-anion radicals like oxygen. The synthesis
and in vitro cytotoxicity of several dinitrophenyl derivatives
of 5-fluorouracil [69, 70], 3-[(2,4-dinitrophenylamino)alkyl]
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derivatives of 5-fluorouracil [71], metronidazole tethered 5-
fluorouracil [72] as radiosensitizers have been described.
These compounds had little or no aerobic cytotoxicity
while showed high cytotoxicity and radiosensitizing effect
under hypoxic conditions.
The radiosensitizing effects of luteolin have been in-
vestigated in H1299 and NCI-H460 non-small cell lung
cancer. Results have shown that inhibition of the cyclin-
dependent kinase 2 by luteolin led to the cell-cycle arrest
and as a consequence activation of the apoptosis. Also
luteolin could inhibit the function of Bcl-2 in B-cell
lymphoma 2 as a pro-apoptotic protein inhibitor and
promote activation of caspase-3, -8 and -9. It has been re-
ported that combination of radiation and luteolin increased
NSLC cell deaths and decreased tumor growth in nude
mice bearing NCI-H460 cell xenograft [73]. Luteolin re-
markably enhanced the radiosensitivity of gastric human
tumors by a significant downregulation of PGE2 produc-
tion and augmentation of the caspase activity simultan-
eously [74]. Plumbagin a naphthoquinone derivative acts
as a radiosensitizer in numerous cancer cell lines like mel-
anoma and cervix cancer. The combination of plumbagine
and 2 Gy of radiation has shown synergism effects and was
more effective in induction of cell deaths as compared to
10 Gy of radiation alone. Plumbagine activates caspase 3
and suppresses Bcl-2 and Bcl-x as anti-apoptotic molecules
without any changes in expression of Bax as pro-apoptotic
protein. In summary, the combination use of sensitizing
agent and IR has more effective in cell growth inhibition as
compared to the use of only higher dose of IR [75].
Neutralization of IAPs (inhibitors of apoptosis proteins)
Recently several approaches for the cancer treatment are
proposed in induction of apoptosis and increases the
radiosensitizing effects through neutralization of IAP.
One of the most important strategies for stimulation of
caspase activation and sensitization of cancer cells to
apoptosis is design and development of a new class of
compounds mimicking endogenous IAP antagonists. By
stimulation of apoptosis second mitochondria-derived
activator of caspase (Smac) also known as DIABLO (dir-
ect IAP binding protein with low pI) is released from
mitochondria into cytosol that antagonizes IAPs as
XIAP, cIAP1 and cIAP2 and also Smac stimulates the ac-
tivation of caspase 3 and subsequently promotes apop-
tosis pathway. Ala-Val-Pro-Ile (AVPI) tetrapeptide in
Smac /DIABLO competes directly with a similar tetra
peptide, Ala-Thr-Pro-Phe (ATPF) motif present in cas-
pase 9, and by binding to a domain in XIAP prevents its
binding to caspases 3, 7 and 9 (Fig. 2) [76]. It has been
proposed that the combination use of a Smac mimetic
and radiation may sensitize cells to killing effects of radi-
ation through neutralization of the activity of IAPs that
result in overcomes apoptosis, causes the release of
cytochrome c and triggers caspase-3 activation in the
following of apoptosome complex formation [77–79].
Recently several Smac mimetics have been introduced to
neutralize IAP proteins and eliminate resistance of lung,
breast, prostate and colorectal carcinoma to IR [79]. For
example, small molecule Smac mimetic Debio 1143 or
SM-406 were shown to be a potent sensitizers of NSCLC
cells to effects of IR-induced apoptosis through cleavages
of caspasse-3, -8 and a decrease in IAPs level. Debio 1143
remarkably enhanced the radiosensitivity by autocrine
TNF-α production in cancer cell lines (Fig. 2). It has been
shown that the release of TNF-α activates bindings of
caspases 3 and 8 to TNFRs and provokes interaction of the
Fas-associating protein with a death domain (FADD)/ re-
ceptor interacting protein 1 (RIP1)/RIP3 which results in
the death of cells by promotion of the apoptosis pathway.
Furthermore it has been shown that the radiosensitization
effects could be potentiated by increase in the drug con-
centration, incubation time and TNF-α stimulation [80]. A
number of XIAP antagonists with nanomolar affinity to
the baculovirus IAP repeat 3 (BIR3) domain of XIAP have
been described which promote apoptosis in resistance can-
cer cell lines and inhibit the growth of tumors in a MDA-
MB-231 breast cancer mouse xenograft model [81]. Also it
has been reported that the use of XIP antagonists increase
the efficacy of radiotherapy by a significant decrease in the
viability of gliobelastoma cells and increase γ-irradiation in-
duced apoptosis by enhancement in cleavage of caspases 3
and 8 into active fragments [82]. BV6 is another small
Smac mimetic-molecule that is radiosensitizer. BV6 is able
to sensitize several glioblastoma cell lines to effects of radi-
ation by stimulation of NF-kB activation, γ-irradiation–
triggered caspase activation, cytochrom C release and in-
crease in mitochondrial outer membrane permeabilization
(MOMP) (Fig. 3) [83, 84]. It has been shown that the Smac
mimetic LCL161 could increase the efficacy of radiother-
apy in esophageal squamous cell carcinoma through the
activation of caspase 8 and down regulation of IAP expres-
sion (Fig. 3) [85]. The efficacy of Smac mimetic SM164 in
sensitization of breast carcinoma and head and neck squa-
mous cells to effects of IR has been demonstrated (Fig. 3)
[86–88]. Mechanistic studies have revealed that exposure
of carcinoma cells to SM164 and radiation results in induc-
tion of apoptosis by activation of caspase cascade pathway
and inhibition of IAP [86].
Survivin is a unique member of IAP family that acts as
an inhibitor of caspase cascade. High expression of survivin
results in suppression of apoptosis which is strongly corre-
lated with radioresistance in most human tumor cells. It
has been suggested that inhibition of survivin results in
radiosensitization in treated cancerous cells [89–91]. For in-
stance, treatment of human epidermoid carcinoma cell line
A431 with adenoviral-mediated wild-type p53, as a survivin
antisense, resulted in radiosensitivity [92]. Attenuation of
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survivin expression is also reported by treatment of human
melanoma cells with a hammerhead ribozyme. Ribozyme
expressing cells which have high sensitivity to effects of
gamma radiation catalytic activity [93]. When siRNA was
applied for downregulation of survivin expression in sar-
coma and pancreatic cancer cell lines, there was an increase
in caspase activity followed by a significant decrease in
radioresistance. As a result this combination therapy per-
haps be useful for the treatment of sarcoma and panceratic
resistance carcinoma [94, 95].
Oxaliplatin is an anti neoplastic drug that is used for
treatment of colorectal cancer. The combination of
oxaliplatin and radiation is another logical strategy to
control proliferation of the head and neck squamous cell
carcinoma (HNSCC) by diminishing survivin expression
and as a result induction of apoptosis through enhance-
ment in caspase-3 activity. Oxaliplatin treatment mark-
edly decreased expression of survivin in cancer cells.
The cytotoxicity of oxaliplatin and radiation combin-
ation was greater than IR or oxaliplatin alone [96].
Radiosensitizing effect of COX-2 inhibitor agents
Several studies demonstrated that COX-2 has a key role in
cell proliferation in cancer cells because its expression
altering function/regulation of pro-apoptotic proteins. It is
cleared that COX-2 selective inhibitor is correlated with
better the tumor growth control and response to radiation
[97]. A well-known mechanism for radiosensitivity activity
of COX-2 inhibitor e.g celecoxib is induction of apoptosis
through reduction of activity/expression pro-survival pro-
teins such as survivin, Bcl-2, Bcl-xl, upregulation the level
of P53, amplifying G2/M phase arrest, activation of intrin-
sic and extrinsic pathways of apoptosis and increase the
level of expression/activation of caspase 8, caspase 9 [56,
60]. Grimes et al. showed nimesulide, a COX-2 selective
inhibitor, has radiosensitivity activity in A549 non-small
cell lung cancer cells and in nude mice bearing A549
tumor xenografts. Nimesulide inhibited NF-κB activity,
with anti-apoptotic effect, that led to down-regulate the
superoxide dismutase (MnSOD) with anti-oxidant activity,
and surviving. Combination treatment with nimesulide
and 30 Gy fractionated radiation resulted to diminish in
tumor size compared with radiation only [98]. In esopha-
geal squamous cell lines TE2 and T.Tn, the combination
of radiation and celecoxib enhanced the radiotherapy effi-
cacy through arresting the G2/M phase, inhibiting the ex-
pression of prostaglandin that has radio-protective effect.
Celecoxib inhibited the DNA repair process and enhanced
the expression/activation of caspase 8 and caspase 3 [99].
Radiosensitivity effect of diclofenac in COX-2 overexpressed
Fig. 2 Chemical structures of Smac AVPI peptide (Second mitochondria-derived activator of caspase Ala-Val-Pro-Ileu) and Debio 1143
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human prostate adenocarcinoma (LNCaP-COX-2) and the
control cell (LNCaP-Neo) was evaluated. LNCaP-COX-2
cells were more resistance to IR than LNCaP-Neo cells.
Their results confirmed the radiosensitivity effect of diclofe-
nac due to reduction the survival fractions at 2 Gy in pres-
ence of diclofenac (35.5%) in comparison with radiation
only (78.6%) in LNCaP-COX-2 cells. Also, insignificant dif-
ferences of radiosensitivity were found in LNCaP-Neo cells
treated with diclofenac. Diclofenac has synergistic effect
with IR through induction TRAIL-induced cell death that
enhances the activation of caspase 8, caspase 9 and caspase
3. Delay in tumor growth was observed in combination of
topical diclofenac gel and radiation than either radiation or
diclofenac only [100]. Decrease the level of COX-2 expres-
sion by NS-398 as a selective COX-2 inhibitor led to
amplyfing G2/M phase arrest in irradiated melanoma cell
lines WM35 and LU1205 and subsequently decrease in
survival of melanoma cells [101]. The radiosensitivity effect
of NS-398 was shown in human prostate carcinoma cells
PC3 with expressing COX-2, not radiosensitivity effect was
seen in COX-2 knockdown PC3 cells [102]. It was shown
that curcumin induced radiosensitivity and apoptosis by
inhibition of survivin and COX-2 and result to activation of
the caspase 3 and down-regulation of prostaglandin E2 sim-
ultaneously [103–105]. The potential role of COX-2
inhibitor to enhance the efficacy of radiotherapy was
reviewed recently [56].
Results of several studies have shown that induction of
the caspase cascade pathway by radiotherapy other than
enhancement of sensitization of tumor cells to effects of
radiation might results in tumor cell re-population that
will be discussed in the next section (Fig. 4) [14, 106, 107].
Radiation-induced tumor cell repopulation: caspase
3-dependent activation of PLA2
Phospholipazes A2 are membrane enzymes that hydrolyze
acyl esters of phospholipids at the sn-2 bond to produce
arachidonic acid and lysophospholipids. These enzymes are
commonly classified into secreted, cytosolic, lipoprotein-
associated and Ca 2+ independent PLA2s [108, 109]. Of
these enzymes the Ca 2+ independent PLA2s have numer-
ous biological activities such as cell differentiation, cell
proliferation, and cell death and it has been reported that
changes in iPLA2 expression results in many disorders
[108–110]. Results of investigation on human PLA2
structure have shown that this peptide has 806 amino acid,
contains an ankyrin-repeat domain, a putative caspase-3
cleavage motifs and a catalytic site [109]. Cleavage of iPLA2
at Asp83 of TNFα/cycloheximide-treated U937 cells results
in excessive release of fatty acids which implies caspase-3-
Fig. 3 Chemical structures of Smac mimetics BV6 (1), LC 161 (2) and SM164 (3)
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mediated activation of iPLA2 [109, 111]. This finding is
important because induction of apoptosis by activation of
caspase cascade might result in migration and proliferation
of malignant cells. As an example it has been shown that
caspase 3 facilitated growth of malignant cells by overex-
pression of iPLA2 [112]. Furthermore repopulation of
surviving cancer cells, as a common obstacle, during the in-
tervals between two doses of radiotherapy is mediated by
caspase 3 [14]. It has been reported that upregulation of
caspase 3 which is induced by radiation other than acting
as an effector to mediate apoptosis, increases significantly
recurrence of cancers and deaths. It has also been shown
that the cells with high expression of executioner caspases
cause wound healing and tissue regeneration through a
pathway called “Phoenix Rising” [113, 114]. Actually activa-
tion of iPLA2, that could be caspase-3 mediated, generates
PGE2 and promotes tumor repopulation (Fig. 4) [14, 113].
Molecular studies have shown that recruitment mac-
rophages that govern elimination of apoptotic cells
after radiotherapy induce tumor repopulation by produc-
tion of a clearance-related cytokine milieu including PGE2
[106, 107, 115]. Results of a recent study showed that after
radiotherapy, the increase in caspase 3, caspase 7 and pro-
tein kinase Cd (PKCd) levels agitate the proliferation of
surviving pancreatic tumor cells [106]. A remarkable re-
duction in recurrence of living cell as compared to wild-
type pancreatic cells has been observed in combination
therapy involving the use of radiation in dominant-
negative mutants of caspase 3 (DN_C3), caspase 7
(DN_C7), or PKCd (DN_PKCδ) [106].
The effect of autophagy stimulators on tumor growth
Autophagy induction is one strategy for reducing tumor
cell repopulation and enhancement of cell death in cells
non-expressing apoptotic regulatory proteins or resist-
ance to multiple apoptotic stimuli [116, 117]. Autophagy
is another form of cell death that could negatively (e.g.
mammalian target of rapamaycin (mTOR), Bcl-2) or
positively (e.g. Beclin, ULK complex (Unc-51-like ki-
nases) regulate [118]. Irradiation of Bax-/Bak- mouse
embryonic fibroblasts (MEF) cells were accompanied
with enhances the level of pro-autophagy proteins such
as Becline-1 and ATG5-ATG12 complex. A markedly
radiosensitizing effect was observed in Bax-/Bak- MEF
cells that was mediated through autophagy induction.
No radiosensitization response was found in MEF cell
treated with 3-methyladenine (3-MA) as an inhibitor of
autophagy. The radiosensitization effect was increased in
cells treated with Rad001 as a mammalian target of rapa-
maycin (mTOR) inhibitor [119]. A significant enhance-
ment in radiation efficacy was found in prostate cancer
cells PC-3 and DU-145 treated with combination rapa-
maycin (mTORI) and Z-VAD (a caspase inhibitor) with
IR [120]. A combination of Z-DEVD (a caspase-3 inhibitor)
and radiation has been reported to enhance radiosenstiza-
tion in a mouse with lung cancer by induction of autoph-
agy pathway [115]. Delay in tumor growth and cellular
proliferation (Ki67 staining), reduce angiogenesis (vWF
staining) and apoptosis (TUNEL staining) confirmed this
radiosensitizing effect that was mediated through induction
autophagy. In summary, recruit of caspase inhibitor with
Fig. 4 A schematic representation of caspase activation resulting in cell death and tumor cell repopulation. Caspase 3 upregulation followed by apoptosis
stimuli lead to iPLA2 (Ca(2+)-independent cytosolic phospholipase A2) activation and cell death. Hydrolysis of fatty acids by iPLA2 results in arachidonic
acid release and production of PGE2 (Prostaglandin E2) a well-known product of cyclooxygenase enzymes which induce tumor cell repopulation
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radiation to stimulate autophagy pathway may be a useful
strategy to increase survival times of patients and a re-
markable delay in tumor recurrence.
The effect of dual COX-2 and EGFR inhibitor on tumor growth
As previously discussed, there is a cross talk between
dual COX-2 and EGFR pathways. Briefly, PGE2 could
transactivate EGFR with several complex processes such
as enhancement the expression of amphiregulin, AKT,
ERK and sarcoma dependent pathways [60–62]. On the
other hand, EGFR could enhance COX-2 expression in
normal and tumor cells such as head and neck squamous
cell carcinoma (HNSCC) cell line mainly through Ras/Raf/
MAPK [121, 122]. Several studies suggested that combin-
ation treatment with EGFR and COX-2 inhibitor led to
more antiangiogenic and antitumor activity with supra-
additive reduction in the levels of multiple pro-survival pro-
teins such as p-ERK1/2, p-EGFR, p-AKT, p-STAT3, COX-2
and PGE2. A synergistic inhibitory effect was shown by
combination treatment with Iressa (EGFR tyrosin kinase in-
hibitor) and SC-236 (COX-2inhibitor) in human breast and
colon cancer lines and in mice bearing colon cancer xeno-
graft [123]. Choe et al. showed the same results in HNSCC
in vitro and in vivo by combination treatment with cele-
coxib and Iressa [124]. Preclinical combined treatment with
erlotinib (EGFR tryrosin kinase inhibitor) and cetuximab
showed significant inhibition in growth of head and neck
cancer cell and animal xenograft model. Tissue biopsy in
preclinical study among patients that received simultan-
eously erlotinib and cetuximab to showed a remarkable
down regulate in pro-survival pathways such as ERK and
AKT [125]. A clinical study among 107 patients with non-
small cell lung cancer that were received erlotinib plus
celecoxib or placebo demonstrated that progression-free
survival was improved between patients receive both erloti-
nib and celecoxib as compared to placebo group [126]. A
supra additive effect in inhibition of clonogenic survival,
apoptosis enhancement and tumor growth suppression was
observed by simultaneously combination treatment with
celecoxib (COX-2I), erlotinib (EGFR inhibitor) and IR in
the HNSCC and phase I clinical study [127].
Conclusion and perspectives
Induction of apoptosis by IR and chemotherapeutic agents
is a known strategy for killing human malignant cells. ROS
that is produced during radiation therapy damage DNA and
as a result trigger apoptotic pathway. Apoptosis induction
through intrinsic and extrinsic pathways leads to caspase
cascade activation. Also the mechanism of action of many
radiosensitizers is based on caspase cascade activation. Cas-
pase 3 act as an execuatior mediator in apoptosis, tumor re-
population through iPLA2 activation and PGE2 production.
Repopulation of tumors results in failure of therapy. Release
of PGE2 upregulates the level of expression of pro-survival
proteins including: p-ERK1/2, p-EGFR, p-AKT, p-STAT3,
COX-2 and PGE-2, which lead to apoptosis suppression and
tumor proliferation. As a hypothesis, caspase 3 has a para-
dox role where its activation results in apoptosis and simul-
taneous acceleration of re-population of surviving tumor
cells. Blockage of caspase 3 activity is a strategy to overcome
radioresistance. On the other hand dependency between
production of apoptosis mediator and increase in PGE2 and
iPLA2 activity is a major reason for the treatment failure in
radiotherapy. Results of investigations have shown that the
use of COX-2 inhibitors may lead to more effective treat-
ment. Furthermore the combination use of EGFR inhibitor
and IR with COX-2 inhibitor is more impressive therapeutic
regimen than the one without EGFR inhibitor. However,
more clinical experiments are required to clarify the advan-
tages of adjuvant use of cyclooxygenase, EGFR or caspase
inhibitor in combination with radiotherapy (Fig. 5).
Fig. 5 A schematic representation of the role of COX-2
(Cyclooxigenases-2) in proliferation of cancer cells. Radiation as well
as PGE2 (Prostaglandin E2) are able to transactivate EGFR (Epidermal
Growth Factor Receptor) that upregulates the level of pro- survival
protein through PI3K/AKT, MAPK/ERK and JAK/STAT pathways.
Also, caspase activation leads to release of arachidonic acid
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Abbreviation
APAF-1: Adapter Protein Apoptotic protease-activating Factor-1; AVPI
peptide: Ala-Val-Pro-Ile (AVPI) tetrapeptide; BIR3: Baculovirus IAP Repeat 3;
c-IAP2: Baculoviral IAP repeat-containing protein3 (also known as cIAP2) is a
protein that in humans is encoded by the BIRC3 gene; c-IAPl: Baculoviral IAP
repeat-containing protein 2 (also known as cIAP1) is a protein that in humans is
encoded by the BIRC2 gene; dATP: Deoxyadenosine triphosphate;
DIABLO: Direct Inhibitor of Apoptosis protein-Binding protein with low pI.
DIABLO is also referred to as second mitochondria-derived activator of
caspases or SMAC.; DN_C3: dominant-negative mutants of caspase 3;
DN_C7: dominant-negative mutants of caspase 7; DN_PKCδ: dominant-
negative mutants of PKCd; ER: Endoplasmic reticulum; FADD: Fas-associating
protein with a death domain; IAP: Inhibitors of apoptosis proteins; iPLA2: Ca(2
+)-independent cytosolic phospholipase A2; lp-PLA2: lipoprotein-associated
PLA2s; mTOR: MammalianTtarget of Rapamaycin; NAIP: Baculoviral IAP
repeat-containing protein 1 is a protein that in humans is encoded by the NAIP
gene; NF-kB: nuclear factor kappa-light-chain-enhancer of activated B cells;
PGE2: Prostaglandin E2; PKCd: Protein kinase C delta type is an enzyme that in
humans is encoded by the PRKCD gene; ROS: Reactive oxygen species; ULK
complex: Serine/threonine-protein kinase ULK1 is an enzyme that in humans is
encoded by the ULK1 gene; SMAC: Second mitochondria-derived activator of
caspases; TNF: Tumor necrosis factor; TNFR1: Tumor necrosis factor receptor-1;
TRAIL: TNF-relatedapoptosis-inducing ligand; XIAP: X-linked inhibitor of
apoptosis protein (XIAP), also known as inhibitor of apoptosis protein 3 (IAP3)
and baculoviral IAP repeat-containing protein 4 (BIRC), is a protein that stops
apoptotic cell death. In humans, this protein (XIAP) is produced by a gene
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